Friday, July 10, 2026

pharma · High-Grade Upper Tract Urothelial Carcinoma

Xiangya Hospital of

Xiangya Hospital of drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
3
Patents
0
Intelligence · Drug Pipeline

Xiangya Hospital of pipeline

Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Xiangya Hospital of drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

3 compounds
  1. Development asset linked to Xiangya Hospital of in public FDA and regional records.

  2. Development asset linked to Xiangya Hospital of in public FDA and regional records.

  3. Development asset linked to Xiangya Hospital of in public FDA and regional records.